Abstract Details
Activity Number:
|
449
|
Type:
|
Contributed
|
Date/Time:
|
Tuesday, August 11, 2015 : 2:00 PM to 2:45 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract #317906
|
|
Title:
|
Missing Data Methods When Analyzing a Phase III Trial in an Orphan Indication
|
Author(s):
|
Changlu Liu* and Mark Baillie and Melanie Wright and Mouna Akacha
|
Companies:
|
Novartis and Novartis and Novartis and Novartis
|
Keywords:
|
Missing data ;
Sensitivity analysis ;
HA discussions
|
Abstract:
|
As health authorities (HA) are becoming increasingly concerned about the impact of missing data on clinical trial outcomes, it is important to consider the robustness of the assumptions when pre-specifying the statistical analysis of a trial. In this presentation, we show a case study of the challenges with dealing with missing data faced when analyzing a Phase III study in an orphan indication. We will discuss the primary and sensitivity analyses of the study in greater depth as well as present the trial results illustrating the robustness of the methodology selected. We will also discuss the challenges that arise due to the small sample sizes of the study and share our experience in discussing these methods with regulators.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2015 program
|
For program information, contact the JSM Registration Department or phone (888) 231-3473.
For Professional Development information, contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
2015 JSM Online Program Home
ASA Meetings Department
732 North Washington Street, Alexandria, VA 22314
(703) 684-1221 • meetings@amstat.org
Copyright © American Statistical Association.